Kinase inhibitors and methods of use
    33.
    发明授权
    Kinase inhibitors and methods of use 有权
    激酶抑制剂和使用方法

    公开(公告)号:US08637542B2

    公开(公告)日:2014-01-28

    申请号:US12920970

    申请日:2009-03-16

    IPC分类号: A01N43/42 A61K31/44

    CPC分类号: C07D471/04 C07D519/00

    摘要: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PB kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.

    摘要翻译: 本发明提供能够调节脂质激酶如PB激酶,软糖激酶和蛋白激酶(例如mTOR)的化学实体或其化合物及其药物组合物。 本发明还提供了使用这些组合物来调节这些激酶,特别是用于治疗应用的方法。

    4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds
    39.
    发明授权
    4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds 有权
    4-羟基-5,6-二氢-1H-吡啶-2-酮化合物

    公开(公告)号:US07834009B2

    公开(公告)日:2010-11-16

    申请号:US11845515

    申请日:2007-08-27

    IPC分类号: C07D417/04 A61K31/549

    CPC分类号: C07D417/04

    摘要: The invention is directed to 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds of Formula I and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus: wherein R6 is X is N, Ring A is a 5- or 6-membered aryl, optionally substituted by 1-3 R8 moieties, n is 2, and R1-R6 and R8 are defined herein.

    摘要翻译: 本发明涉及式I的4-羟基-5,6-二氢-1H-吡啶-2-酮化合物和含有可用于治疗丙型肝炎病毒感染的化合物的药物组合物:其中R6是X是N, 环A是5-或6-元芳基,任选被1-3个R8部分取代,n是2,R1-R6和R8如本文所定义。

    Pyridazinone compounds
    40.
    发明授权
    Pyridazinone compounds 有权
    哒嗪酮化合物

    公开(公告)号:US07425552B2

    公开(公告)日:2008-09-16

    申请号:US11304902

    申请日:2005-12-16

    摘要: The invention is directed to pyridazinone compounds of Formula I and pharmaceutical compositions containing compounds of Formula I wherein R1 and R2 are independently H, alkyl, cycloalkyl, aryl, or heterocyclyl; and Ring A is 5 or 6-membered aryl or heterocyclyl. The invention also encompasses methods of using a compound of Formula I in the treatment of hepatitis C virus infections.

    摘要翻译: 本发明涉及式I的哒嗪酮化合物和含有式I化合物的药物组合物,其中R 1和R 2独立地为H,烷基,环烷基,芳基或杂环基 ; 环A为5或6元芳基或杂环基。 本发明还包括使用式I化合物治疗丙型肝炎病毒感染的方法。